Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:PACB
Previous Symbol
CUSIP69404D10
Phone650-521-8000
Debt
Debt-to-Equity Ratio0.11
Current Ratio6.65
Quick Ratio5.74
Price-To-Earnings
Trailing P/E Ratio-8.67
Forward P/E Ratio-11.09
P/E GrowthN/A
Sales & Book Value
Annual Sales$93.47 million
Price / Sales12.01
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.74 per share
Price / Book10.19
Profitability
EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-110.10%
Return on Equity-91.12%
Return on Assets-59.60%
Miscellaneous
Employees456
Outstanding Shares148,900,000
Market Cap$1.12 billion
OptionableOptionable
Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $18.16 million for the quarter, compared to analyst estimates of $22.39 million. Pacific Biosciences of California had a negative return on equity of 91.12% and a negative net margin of 110.10%. The business's quarterly revenue was down 22.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.19) EPS. View Pacific Biosciences of California's Earnings History.
When is Pacific Biosciences of California's next earnings date?
What price target have analysts set for PACB?
3 equities research analysts have issued 1 year price targets for Pacific Biosciences of California's stock. Their forecasts range from $3.80 to $8.00. On average, they expect Pacific Biosciences of California's share price to reach $6.10 in the next year. This suggests that the stock has a possible downside of 19.2%. View Analyst Price Targets for Pacific Biosciences of California.
What is the consensus analysts' recommendation for Pacific Biosciences of California?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California.
What are Wall Street analysts saying about Pacific Biosciences of California stock?
Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
- 1. Cantor Fitzgerald analysts commented, ": We are downgrading the shares of PACB to PACB’s announced acquisition by ILMN (Not Covered). On Nov. 1, after the market close, PACB announced an agreement to be acquired by ILMN for $8 per share, or ~$1.2B total EV. We view the likelihood of a higher bidder to be low. We also think regulatory risk to the deal remains low. The acquisition is expected to be completed mid-2019. We spoke to a number of industry participants to assess the likelihood of a higher bidder and regulatory approval." (11/12/2018)
- 2. According to Zacks Investment Research, "Pacific Biosciences saw a dreary second quarter. However, the company witnessed strong bookings for Sequel in the quarter. Constant instrument orders from BGI and China are encouraging. Furthermore, the company is well poised on expansion of SMRT Sequencing and product development activities. On the flip side, Product and service revenues deteriorated on a year-over-year basis due to lower instrument revenues. Dull performance in the other revenue segment is a concern. The DNA sequencing market is rife with competition. Sales in Europe declined considerably. Also, higher operating expenses are a headwind. The stock is currently overvalued. The company has also not provided any guidance for the upcoming quarters. Pacific Biosciences has underperformed the industry in a year’s time. Pacific Biosciences underperformed the industry in a year’s time." (8/6/2018)
Has Pacific Biosciences of California been receiving favorable news coverage?
Media coverage about PACB stock has been trending very positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacific Biosciences of California earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the folowing people:
- Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
- Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
- Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
- Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
- Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)
Who are Pacific Biosciences of California's major shareholders?
Pacific Biosciences of California's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.70%), ARK Investment Management LLC (5.90%), Vanguard Group Inc. (4.24%), Point72 Asset Management L.P. (3.48%), Capital World Investors (3.14%) and Capital International Investors (2.80%). View Institutional Ownership Trends for Pacific Biosciences of California.
Which institutional investors are selling Pacific Biosciences of California stock?
PACB stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Trellus Management Company LLC, TIAA CREF Investment Management LLC, ING Groep NV, Frontier Capital Management Co. LLC, Mutual of America Capital Management LLC, Compagnie Lombard Odier SCmA and Credit Suisse AG. View Insider Buying and Selling for Pacific Biosciences of California.
Which institutional investors are buying Pacific Biosciences of California stock?
PACB stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Bellevue Group AG, Point72 Asset Management L.P., ARK Investment Management LLC, Foresite Capital Management III LLC, Lombard Odier Asset Management USA Corp, Panagora Asset Management Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Pacific Biosciences of California.
How do I buy shares of Pacific Biosciences of California?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacific Biosciences of California's stock price today?
One share of PACB stock can currently be purchased for approximately $7.55.
How big of a company is Pacific Biosciences of California?
Pacific Biosciences of California has a market capitalization of $1.12 billion and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.
What is Pacific Biosciences of California's official website?
How can I contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]
MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
